Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China

Charlotte Atkinson, Roberta M. Ray, Wenjin Li, Ming Gang Lin, Dao Li Gao, Jackilen (Jackie) Shannon, Helge Stalsberg, Peggy L. Porter, Cara L. Frankenfeld, Kristiina Wähälä, David B. Thomas, Johanna W. Lampe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Equol (a bacterial metabolite of the soy isoflavone daidzein) is produced by 30% to 50% of humans and may be associated with health outcomes. We hypothesized that plasma equol would be inversely associated with risks of fibrocystic breast conditions (FBC) and breast cancer (BC). Plasma from women in a breast self-examination trial in Shanghai with BC (n = 269) or FBC (n = 443), and age-matched controls (n = 1027) was analyzed for isoflavones. Equol was grouped into categories (10 equol:daidzein ratio was grouped into tertiles. Where available, non-cancerous tissue (NCT) adjacent to the carcinomas from women with BC were classified as non-proliferative or proliferative (n = 130 and 172, respectively). The lesions from women with FBC were similarly classified (n = 99 and 92, respectively). Odds ratios (OR) and 95% confidence intervals (CI) were calculated across equol categories and tertiles of log10 equol:daidzein ratio. Equol categories were not associated with FBC or BC (P > .05). For log10 equol:daidzein, compared to controls there were positive associations in the mid tertile for proliferative FBC (OR 2.06, 95% CI 1.08-3.93), BC with proliferative NCT (OR 2.95, 95% CI 1.37-6.35), and all BC regardless of histology (OR 2.37, 95% CI 1.43-3.95). However, trends in ORs with increasing plasma equol values or equol:daidzein ratios were not observed (P > .05). The results of this study do not provide evidence that equol plays a role in the etiology of these breast conditions. However, further work is needed to confirm or refute this conclusion.

Original languageEnglish (US)
Pages (from-to)863-871
Number of pages9
JournalNutrition Research
Volume36
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Equol
China
Breast Neoplasms
Breast
Odds Ratio
Confidence Intervals
Isoflavones
Breast Self-Examination

Keywords

  • Breast cancer
  • Daidzein
  • Equol
  • Fibrocystic changes in the breast
  • Isoflavone
  • Nested case-control study
  • Women

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China. / Atkinson, Charlotte; Ray, Roberta M.; Li, Wenjin; Lin, Ming Gang; Gao, Dao Li; Shannon, Jackilen (Jackie); Stalsberg, Helge; Porter, Peggy L.; Frankenfeld, Cara L.; Wähälä, Kristiina; Thomas, David B.; Lampe, Johanna W.

In: Nutrition Research, Vol. 36, No. 8, 01.08.2016, p. 863-871.

Research output: Contribution to journalArticle

Atkinson, C, Ray, RM, Li, W, Lin, MG, Gao, DL, Shannon, JJ, Stalsberg, H, Porter, PL, Frankenfeld, CL, Wähälä, K, Thomas, DB & Lampe, JW 2016, 'Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China', Nutrition Research, vol. 36, no. 8, pp. 863-871. https://doi.org/10.1016/j.nutres.2016.03.008
Atkinson, Charlotte ; Ray, Roberta M. ; Li, Wenjin ; Lin, Ming Gang ; Gao, Dao Li ; Shannon, Jackilen (Jackie) ; Stalsberg, Helge ; Porter, Peggy L. ; Frankenfeld, Cara L. ; Wähälä, Kristiina ; Thomas, David B. ; Lampe, Johanna W. / Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China. In: Nutrition Research. 2016 ; Vol. 36, No. 8. pp. 863-871.
@article{69696f2915b24357abbc6be1c5adbbc4,
title = "Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China",
abstract = "Equol (a bacterial metabolite of the soy isoflavone daidzein) is produced by 30{\%} to 50{\%} of humans and may be associated with health outcomes. We hypothesized that plasma equol would be inversely associated with risks of fibrocystic breast conditions (FBC) and breast cancer (BC). Plasma from women in a breast self-examination trial in Shanghai with BC (n = 269) or FBC (n = 443), and age-matched controls (n = 1027) was analyzed for isoflavones. Equol was grouped into categories (10 equol:daidzein ratio was grouped into tertiles. Where available, non-cancerous tissue (NCT) adjacent to the carcinomas from women with BC were classified as non-proliferative or proliferative (n = 130 and 172, respectively). The lesions from women with FBC were similarly classified (n = 99 and 92, respectively). Odds ratios (OR) and 95{\%} confidence intervals (CI) were calculated across equol categories and tertiles of log10 equol:daidzein ratio. Equol categories were not associated with FBC or BC (P > .05). For log10 equol:daidzein, compared to controls there were positive associations in the mid tertile for proliferative FBC (OR 2.06, 95{\%} CI 1.08-3.93), BC with proliferative NCT (OR 2.95, 95{\%} CI 1.37-6.35), and all BC regardless of histology (OR 2.37, 95{\%} CI 1.43-3.95). However, trends in ORs with increasing plasma equol values or equol:daidzein ratios were not observed (P > .05). The results of this study do not provide evidence that equol plays a role in the etiology of these breast conditions. However, further work is needed to confirm or refute this conclusion.",
keywords = "Breast cancer, Daidzein, Equol, Fibrocystic changes in the breast, Isoflavone, Nested case-control study, Women",
author = "Charlotte Atkinson and Ray, {Roberta M.} and Wenjin Li and Lin, {Ming Gang} and Gao, {Dao Li} and Shannon, {Jackilen (Jackie)} and Helge Stalsberg and Porter, {Peggy L.} and Frankenfeld, {Cara L.} and Kristiina W{\"a}h{\"a}l{\"a} and Thomas, {David B.} and Lampe, {Johanna W.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.nutres.2016.03.008",
language = "English (US)",
volume = "36",
pages = "863--871",
journal = "Nutrition Research",
issn = "0271-5317",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China

AU - Atkinson, Charlotte

AU - Ray, Roberta M.

AU - Li, Wenjin

AU - Lin, Ming Gang

AU - Gao, Dao Li

AU - Shannon, Jackilen (Jackie)

AU - Stalsberg, Helge

AU - Porter, Peggy L.

AU - Frankenfeld, Cara L.

AU - Wähälä, Kristiina

AU - Thomas, David B.

AU - Lampe, Johanna W.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Equol (a bacterial metabolite of the soy isoflavone daidzein) is produced by 30% to 50% of humans and may be associated with health outcomes. We hypothesized that plasma equol would be inversely associated with risks of fibrocystic breast conditions (FBC) and breast cancer (BC). Plasma from women in a breast self-examination trial in Shanghai with BC (n = 269) or FBC (n = 443), and age-matched controls (n = 1027) was analyzed for isoflavones. Equol was grouped into categories (10 equol:daidzein ratio was grouped into tertiles. Where available, non-cancerous tissue (NCT) adjacent to the carcinomas from women with BC were classified as non-proliferative or proliferative (n = 130 and 172, respectively). The lesions from women with FBC were similarly classified (n = 99 and 92, respectively). Odds ratios (OR) and 95% confidence intervals (CI) were calculated across equol categories and tertiles of log10 equol:daidzein ratio. Equol categories were not associated with FBC or BC (P > .05). For log10 equol:daidzein, compared to controls there were positive associations in the mid tertile for proliferative FBC (OR 2.06, 95% CI 1.08-3.93), BC with proliferative NCT (OR 2.95, 95% CI 1.37-6.35), and all BC regardless of histology (OR 2.37, 95% CI 1.43-3.95). However, trends in ORs with increasing plasma equol values or equol:daidzein ratios were not observed (P > .05). The results of this study do not provide evidence that equol plays a role in the etiology of these breast conditions. However, further work is needed to confirm or refute this conclusion.

AB - Equol (a bacterial metabolite of the soy isoflavone daidzein) is produced by 30% to 50% of humans and may be associated with health outcomes. We hypothesized that plasma equol would be inversely associated with risks of fibrocystic breast conditions (FBC) and breast cancer (BC). Plasma from women in a breast self-examination trial in Shanghai with BC (n = 269) or FBC (n = 443), and age-matched controls (n = 1027) was analyzed for isoflavones. Equol was grouped into categories (10 equol:daidzein ratio was grouped into tertiles. Where available, non-cancerous tissue (NCT) adjacent to the carcinomas from women with BC were classified as non-proliferative or proliferative (n = 130 and 172, respectively). The lesions from women with FBC were similarly classified (n = 99 and 92, respectively). Odds ratios (OR) and 95% confidence intervals (CI) were calculated across equol categories and tertiles of log10 equol:daidzein ratio. Equol categories were not associated with FBC or BC (P > .05). For log10 equol:daidzein, compared to controls there were positive associations in the mid tertile for proliferative FBC (OR 2.06, 95% CI 1.08-3.93), BC with proliferative NCT (OR 2.95, 95% CI 1.37-6.35), and all BC regardless of histology (OR 2.37, 95% CI 1.43-3.95). However, trends in ORs with increasing plasma equol values or equol:daidzein ratios were not observed (P > .05). The results of this study do not provide evidence that equol plays a role in the etiology of these breast conditions. However, further work is needed to confirm or refute this conclusion.

KW - Breast cancer

KW - Daidzein

KW - Equol

KW - Fibrocystic changes in the breast

KW - Isoflavone

KW - Nested case-control study

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84976877505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976877505&partnerID=8YFLogxK

U2 - 10.1016/j.nutres.2016.03.008

DO - 10.1016/j.nutres.2016.03.008

M3 - Article

VL - 36

SP - 863

EP - 871

JO - Nutrition Research

JF - Nutrition Research

SN - 0271-5317

IS - 8

ER -